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Summary
Clinical hip abnormalities, secondary to recurrent joint and/or muscle bleeding in persons with 
haemophilia, have not been well characterized and have the potential for significant morbidity. We 
aimed to examine the prevalence of clinical hip abnormalities in the US haemophilia population 
and to explore associations between these findings and putative risk factors. We conducted a study 
of hip abnormalities of 8192 subjects aged 2–69 years with haemophilia A and haemophilia B 
(54% of haemophilia A and haemophilia B are severe) currently enrolled in the Universal Data 
Collection (UDC) database. Associations between hip abnormality and type/severity of 
haemophilia A/B, current age, history of high-titre (≥5 BU) inhibitor (HTinh), concomitant ankle 
(AA) and knee arthropathy (KA), overweight and obesity and prophylaxis were examined using 
logistic regression. Overall prevalence of hip abnormality at the last recorded UDC visit for all 
subjects was 16.7%. Haemophilia A (aOR = 1.3, 1.0–1.4), severe haemophilia (aOR = 1.3, 1.0–
1.5), a history of HTinh (aOR = 1.4, 1.1–1.7), and concomitant AA (aOR = 1.7, 1.4–1.9) were 
each independently associated with hip abnormality. Older age (45–69 years) was significantly 
associated with hip abnormality prevalence only in subjects with KA (aOR = 3.4, 1.9–5.9). The 
presence of overweight (aOR = 1.4, 1.1–1.8) and obesity (aOR = 2.1, 1.6–2.8) was associated with 
hip abnormality only among subjects without KA. Hip abnormality prevalence was not influenced 
by prophylaxis (aOR = 0.9, 0.8–1.1). These data suggest that hip abnormalities in US patients with 
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haemophilia are associated with haemophilia severity and type, HTinh, concomitant AA and, 
depending on the presence or absence of KA, advancing age and obesity.
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Introduction
The development of chronic pain and limited motion secondary to recurrent joint and muscle 
bleeding causes significant morbidity in persons with haemophilia. Overall, patients with the 
musculoskeletal complications of haemophilia are more likely to have had early and 
recurrent ankle, knee or elbow haemarthroses; hip abnormalities, when they occur, generally 
manifest at an older age [1]. Although less common, hip abnormalities serve as a significant 
source of impaired mobility. Joint and muscle bleeding around the hip could pose a 
particularly significant problem in the paediatric population as prior studies indicate that 
arthropathy developing in childhood results in more severely destructive hip disease than 
that occurring after 20 years of age [2].
Although the risk factors for hip dysfunction in haemophilia remain poorly understood, 
ancillary factors known to generally affect haemophilic joint morbidity may impact this 
phenomenon [3,4]. Prophylactic factor administration has been shown to prevent joint 
destruction and to decrease the frequency of all joint haemorrhage [5–8]. However, among 
patients with severe haemophilia who develop high-titre inhibitors of ≥5 Bethesda Units 
(BU), effective prophylaxis is more difficult to achieve and overall morbidity, including 
haemophilic arthropathy, is often more pronounced [4,9]. Furthermore, in the US children 
and adults exhibit an increasingly sedentary lifestyle with an associated increased likelihood 
of obesity [10]. The potential influence of this national trend on range of motion (ROM), 
and secondarily, on predisposition to haemorrhage, in joints is concerning. Recently 
published studies demonstrated that obese males with haemophilia A had lower ROM and a 
faster rate of loss of joint mobility in the lower limbs compared with those with a normal 
body mass index (BMI) [3,11]. The impact of knee and ankle arthropathy on hip disease in 
haemophilia has not been documented to date.
Based on recent institutional experience with hip haemarthroses in several children aged 1–
10 years of age, we sought to examine the national prevalence of hip abnormalities in US 
children and adults with severe, moderate and mild haemophilia A and haemophilia B who 
are currently enrolled in the Center for Disease Control and Prevention’s Universal Data 
Collection (UDC) database. The UDC project is a surveillance database of over 14 000 
patients with haemophilia treated at federally funded Hemophilia Treatment Centers (HTC), 
and includes joint ROM on 96% of enrolled subjects [12,13]. We also sought to evaluate the 
prevalence of hip abnormalities relative to potentially important comorbidities including 
advancing age; a history of high-titre inhibitor; concomitant prevalence of abnormal ROM 
in knee and ankle and elevated BMI. A better understanding of this haemophilic 
complication and the identification of its potential risk factors could allow for targeted 
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therapy and lifestyle adjustments aimed at reducing risk of hip joint abnormality and 
associated morbidity.
Methods
The UDC project, initiated in 1998, is a surveillance database containing demographic and 
clinical information on over 14 000 patients with haemophilia treated at a network of 
specialized HTC, and includes joint ROM measurements on 96% of enrolled subjects 
[12,13]. All male UDC participants with severe, moderate and mild haemophilia A and 
haemophilia B, enrolled in the UDC database between 1998 and 2008, and aged 2–69 years 
at the time of their last visit, were eligible for inclusion in the study. The study examined the 
relationship between demographic and clinical characteristics of the population and the 
prevalence of documented or suggested hip abnormalities. Hip abnormality was defined by: 
(i) a deficit in hip ROM at the last recorded UDC visit, and/or (ii) designation of the hip as a 
target joint at the last recorded visit, and/or (iii) joint replacement/fusion as recorded at any 
UDC visit during the study period. Deficit in hip ROM was determined for each subject and 
defined as a ROM that was at least 3 standard deviations below the mean normal ROM for 
hip flexion and/or extension for his age group individuals [14]. Joint-specific bleeding data, 
including bleeding site and frequency, are not captured in the UDC data set. To better define 
hip abnormality in the absence of such data, subjects with bilateral hip ROM deficits were 
excluded from the analysis unless the deficit was corroborated by concomitant target joint 
designation or hip replacement in at least one hip joint. In this way, we attempted to 
minimize the likelihood of inappropriately including bilateral deficits in hip ROM not due to 
haemorrhage, (e.g. muscle tightness, increased body mass, inactivity), in the analysis. 
Similarly, the lack of site-specific bleeding data precluded the exclusion from analysis of 
residual deficits in hip ROM from prior hip flexor or extensor muscle and connective tissue 
haemorrhage. Therefore, we chose to use the term ‘hip abnormality’ to encompass both the 
intra-articular and extra-articular complications of bleeding into the hip area.
Hip abnormality was examined relative to the following comorbidity variables: advancing 
age; history of high-titre inhibitor; presence of knee and ankle arthropathy and BMI. In 
addition, haemophilia type and severity were examined. Finally, the prevalence of hip 
abnormalities was examined in subjects with severe haemophilia A and haemophilia B and 
no history of an inhibitor who were receiving continuous prophylaxis at the first UDC visit 
and compared with those subjects who received only on-demand (episodic) treatment.
Definition of variables
Knee or ankle arthropathy was defined as the presence of either abnormal knee/ankle ROM 
or designation of the knee/ankle as a target joint at the visit before the last recorded UDC 
visit or indication at any UDC visit that any knee replacement or ankle fusion had been 
performed. This served as a surrogate marker for overall severity of arthropathy. Abnormal 
ROM was defined as a decrease of >3 standard deviations below the mean age-specific 
normal ROM for knee flexion and/or extension, and ankle dorsiflexion and/or plantar 
flexion [14].
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High-titre inhibitor positivity was defined by at least 1 historical peak titre of >5 BU 
recorded at any time during the data collection period [15].
BMI (weight in kilograms/height in metres squared) was calculated at baseline to categorize 
weight status. Adults aged 20–69 years with BMIs of 12 to <25 were considered 
underweight to normal; those with 25 to <30 were classified as overweight and those with 
≥30 were determined to be obese. For children and adolescents aged 2–19 years, we used the 
US Centers for Disease Control and Prevention (CDC) recommended percentile guidelines 
for children’s BMI classification, which takes into consideration normal differences in body 
fat between boys and girls at various ages, as follows: underweight to normal weight (<5th–
84th percentile); overweight (85th–95th percentile) and obese (>95th percentile) [16].
Prophylaxis was defined as having received treatment products on a regular schedule for an 
indefinite period to prevent any and all bleeding. This definition would encompass current 
definitions of primary and secondary prophylaxis, which could not be distinguished in this 
data set. Subjects who had not received continuous prophylaxis at time of the first UDC visit 
were defined as receiving episodic (on-demand) therapy.
Statistical analysis
The prevalence of hip abnormality and its components were calculated for each age and 
severity level. Pearson’s chi-squared tests or Fisher exact test was used to assess the 
statistical significance of associations between HAbn and levels of demographic and clinical 
characteristics.
Multivariate associations were analysed using logistic regression analysis. The logistic 
regression model included all of the studied risk factors and statistical interactions between 
variables were assessed by entering interaction terms in the model. Adjusted odds ratios 
(aOR) of hip abnormality and 95% confidence intervals were computed. Stratified odds 
ratios were presented when statistically significant interaction (effect modification) was 
identified. All statistical analyses were based on two-sided tests with a significance level of 
0.05, and conducted using SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
The study included 8192 subjects aged 2–69 years (51% aged 2–19 years) with haemophilia 
A (78%) and haemophilia B of all severities (54% are severe) enrolled in the UDC database 
between 1998 and 2008. Hip abnormality was found in 1372/8192 (17%) of all evaluated 
haemophilic subjects (Table 1). The prevalence of hip abnormality in children aged 2–8 
years was 7% (94/1328), and was defined solely by abnormal hip ROM in 87/94 (93%) of 
the youngest subjects. Hip abnormality defined on the basis of hip replacement or target 
joints was much less frequent and occurred almost exclusively in subjects over the age of 20 
years.
Associations between subject demographic and clinical characteristics and hip abnormality 
are shown in Table 2. A significant increase in the prevalence of hip abnormality was noted 
in association with increasing age and haemophilia severity (P < 0.0001), in subjects with 
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haemophilia A as compared with haemophilia B (18% vs. 14% P = 0.0003), among subjects 
with a positive history of a high-titre inhibitor (22% vs. 16%, P = 0.0007), among those who 
were overweight or obese as compared with non-overweight (20%, 24% vs. 16% P < 
0.0001) and among those with concomitant knee (25% vs. 11%, P < 0.0001) and ankle 
arthropathy (24% vs. 11%, P < 0.0001) (Table 2). However, there was no significant 
difference in hip abnormalities among those subjects receiving continuous prophylaxis 
(17%) when compared with those who had received only episodic (on-demand) therapy 
(16%, P = 0.47).
To evaluate the independent associations between the studied demographic and clinical 
characteristics and hip abnormality, a logistic regression model was utilized. We found 
statistical interaction (effect modification) between concomitant knee arthropathy and both 
age and BMI. This meant that the strength of the associations between age and hip 
abnormality and separately, BMI and hip abnormality, was different depending on the 
presence or absence of knee arthropathy. Therefore, we present stratum-specific odds ratios 
for both age and BMI in Table 3.
Haemophilia A (aOR = 1.3, 1.0–1.4), severe haemophilia (aOR = 1.3, 1.0–1.5), a high-titre 
inhibitor (aOR = 1.4, 1.1–1.7) and concomitant ankle arthropathy (aOR = 1.7, 1.4–1.9) were 
each independently associated with the presence of hip abnormality (Table 3). Among 
subjects without concomitant knee arthropathy, subjects who were 9–19 years old were 
more likely than those who were 2–8 years old to have hip abnormalities (aOR = 1.7, 1.2–
2.5). In contrast, among those with knee arthropathy only the 45–69-year-old subjects were 
more likely than the youngest subjects to have hip abnormalities (aOR = 3.4, 1.9–5.9).
Concomitant knee arthropathy also influenced associations between BMI and hip 
abnormality (Table 3). Overweight (aOR = 1.4, 1.1–1.8) and obese subjects (aOR = 2.1, 
1.6–2.8) without knee arthropathy were 1.4 times and 2 times more likely than their normal 
weight counterparts to have hip abnormalities. However, there was not a significantly 
increased likelihood of hip abnormalities among either overweight or obese subjects who 
also had knee arthropathy.
Discussion
The prevalence of hip abnormalities in haemophilia has not been characterized in the context 
of the availability of more intensive coagulation factor replacement therapy. In this study, 
we performed such an evaluation in a US haemophilia cohort that has undergone 
surveillance for the prevalence of disease- and treatment-related complications of the 
disorder. However, as discussed in the Methods section of this manuscript, the definitions of 
hip dysfunction required modification to compensate for the lack of site-specific bleeding 
data. The term ‘hip abnormality’ was therefore chosen to encompass both the intra-articular 
and extra-articular morbidity that could contribute to unilateral loss of ROM.
Within the context of the methodological limitations, we report an overall prevalence of hip 
abnormality in this US haemophilia population of 16.7%. This is a lower prevalence than 
that observed in this cohort for both knee (42%) and ankle (45%) arthropathy, but possibly 
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more frequent than anticipated in persons with haemophilia. Furthermore, the long-term 
morbidity associated with overt hip arthropathy appears to be significant. Among older 
adults in the study sample, 5% had experienced target joint bleeding in a hip and 7% 
required a replacement of at least one hip.
Our initial clinical observation of hip abnormality in very young children was corroborated 
by the observed prevalence of 7% in the youngest study sub-cohort. However, the low hip 
abnormality prevalence was somewhat reassuring. Nonetheless, as developing joints may be 
more prone to destructive arthropathy with minimal bleeding [17], these data also suggest 
that caregivers should be alert to symptoms of local pain and unilateral decreased hip ROM 
as possible signs of hip haemarthrosis or haemorrhage into large muscle groups in the area 
(e.g. iliopsoas), even in a very young child without other lower extremity arthropathy.
Although the database did not allow us to examine predisposing events or risk factors, we 
were able to evaluate potentially associated comorbid conditions, related and unrelated to 
haemophilia. Not surprisingly, haemophilia severity and positive high-titre inhibitor status, 
variables known to be associated with overall increased orthopaedic morbidity, were also 
associated with significantly higher hip abnormality prevalence in this study. The increased 
association of hip abnormality with underlying haemophilia A when compared with 
haemophilia B corroborates the Italian observations of Iorio et al. [18]. However, 
prophylaxis intervention was not a significant modifying factor in our study. This 
observation likely relates to the nature of a surveillance data collection limited by 
nomenclature adopted prior to the widespread use of prophylaxis in the United States. 
Although a more precise classification was unavailable for inclusion in our analysis, it 
remains likely that much of the ‘continuous’ prophylactic use of factor in our data set 
reflected the late initiation of secondary prophylaxis similarly described in the international 
orthopaedic study by Aledort et al. [7].
In this US cohort, 20% of subjects were overweight and 12% were obese, according to well-
defined criteria. In excluding bilateral decreased hip ROM that may have been due to 
elevated BMI alone, we were able to examine and ascertain a very strong independent 
association between hip abnormality and this variable, particularly obesity. This association 
remained highly significant, except in the presence of concomitant knee arthropathy. These 
results would suggest that the impact of knee arthropathy on the development of hip 
abnormalities is more significant than overweight and obesity for patients in whom both 
conditions coexist. Consequently, the association between excess weight and hip 
abnormalities is best observed in patients without knee arthropathy as a complication of their 
haemophilia.
The relationship between elevated BMI and hip abnormality is likely complex; each 
condition has the potential to influence the other. Nonetheless, the growing rates of obesity 
among the general population demonstrate an alarming trend [19,20]. Based on previously 
published data, this trend may be even more problematic among those individuals with 
haemophilia [11]. Several of the comorbidities associated with hip abnormality cannot be 
easily manipulated; however, altering lifestyle choices to maintain a normal BMI for age 
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could represent an important means of maintaining overall orthopaedic health in persons 
with haemophilia.
The significant direct correlation observed between hip abnormality and both advancing age 
as well as concomitant lower extremity arthropathy was also expected. However, we did not 
anticipate the strength of the association between hip abnormality and knee arthropathy. 
Concomitant knee arthropathy appeared to be primarily responsible for the significant age-
related association with hip abnormality in the adult subgroups in our study. The 
interpretation of these findings is again limited by the nature of the data. Nonetheless, these 
data do suggest the potential importance of preventing knee arthropathy in the maintenance 
of normal hip ROM.
The subgroup of haemophilia subjects aged 9–19 years warrants further discussion. The 
prevalence of hip abnormality in this age group was 15%, double that observed in the 
youngest cohort. As with the youngest subjects, the majority of the hip abnormality in this 
sub-group (96%) was defined by significant unilateral loss of hip ROM. Importantly, absent 
knee or ankle arthropathy did not appear to modify this significant age effect. Given that our 
definition of hip abnormality encompassed limitations in both intraarticular hip and extra-
articular muscle and connective tissue morbidity, these subjects may have experienced 
altered hip mechanics from more muscle (including iliopsoas) and groin tissue bleeding 
associated with greater sports-related activity, parameters that we could not measure. In 
addition, in a prior recent study of the UDC cohort, subjects aged 2–20 were noted to have a 
15% and 17.4% prevalence of overweight and obesity, respectively [11]. Both states of 
elevated BMI were noted in that study to independently and statistically correlate with loss 
of ROM over time [11]. Obesity prevalence in the younger subjects trends higher than that 
for this study population as a whole (12%). Although bilateral loss of hip ROM was 
excluded in this study to minimize the effect of BMI alone, increased BMI compared with 
the cohort as a whole could have been partially responsible for the results observed in this 
age group.
Limitations
In addition to the study limitations already described, the UDC database could not identify 
other potential confounders of our analysis. These included unrelated ancillary conditions 
that may specifically affect hip ROM (e.g. HLA-B27 spondylarthropathy, Gaucher Disease 
and Legg-Calve-Perthes Disease). However, the most common among these is Legg-Calve-
Perthes disease which occurs with an estimated frequency of 0.4–15.4/100 000 among 
patients less than 15 years of age and is unlikely to have significantly affected the 
epidemiology of loss of hip ROM in a haemophilia population [11,21]. The most potentially 
confounding condition among haemophilia-related causes of loss of hip ROM would indeed 
be iliopsoas muscle haemorrhage, which has been reported to occur at an annual incidence 
rate of 2.9/1000 patients with severe or moderate haemophilia A [22]. The potential 
confounding effect of this variable has been discussed.
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We conclude that among subjects enrolled in the UDC database, hip abnormality accounts 
for an appreciable amount of orthopaedic morbidity. As might have been anticipated, 
advancing age, haemophilia severity and type, positive high-titre inhibitor status and 
elevated BMI were all factors associated with increased prevalence of hip abnormality, as 
defined in this study. Surprisingly, concomitant knee arthropathy proved to be a strongly 
associated comorbidity. However, given the limitations of this study, prospective 
longitudinal data collection that includes joint-specific haemorrhage as well as more robust 
markers of arthropathy will be required to both confirm the prevalence of specific hip 
arthropathy and further define its risk factors, particularly in the younger population in 
whom early intervention would minimize long-term morbidity.
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Table 2
Comparison of demographic and clinical characteristics in patients with and without hip abnormality.
Total (N = 8192)
N (% of column)
Hip abnormality (N = 1372)
N (% of row)
Normal (N = 6820)
N (% of row) P value*
Age
 2–8 years 1328 (16) 94 (7) 1234 (93) <0.0001
 9–19 years 2861 (35) 444 (16) 2417 (84)
 20–44 years 2945 (36) 537 (18) 2408 (82)
 45–69 years 1058 (13) 297 (28) 761 (72)
Haemophilia type
 Haemophilia A 6419 (78) 1125 (18) 5294 (82) 0.0003
 Haemophilia B 1773 (22) 247 (14) 1526 (86)
Haemophilia severity
 Mild 1844 (23) 226 (12) 1618 (88) <0.0001
 Moderate 1942 (24) 312 (16) 1630 (84)
 Severe 4406 (54) 834 (19) 3572 (81)
Positive history of a high-titre inhibitor
 No 7630 (93) 1248 (16) 6382 (84) 0.0007
 Yes 562 (7) 124 (22) 438 (78)
Baseline BMI†
 Normal 5094 (69) 806 (16) 4288 (84) <0.0001
 Overweight 1446 (20) 292 (20) 1154 (80)
 Obese 851 (12) 200 (24) 651 (76)
Concomitant knee arthropathy†
 No 4618 (58) 519 (11) 4099 (89) <0.0001
 Yes 3338 (42) 836 (25) 2502 (75)
Concomitant ankle arthropathy†
 No 4318 (55) 485 (11) 3833 (89) <0.0001
 Yes 3602 (45) 865 (24) 2737 (76)
Prophylaxis
 No 2024 (25) 328 (16) 1696 (84) 0.4713
 Yes 6168 (75) 1044 (17) 5124 (83)
*
P value is calculated by Pearson’s chi-squared test.
†
Relevant data missing for some subjects.
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Table 3
Independent associations between hip abnormality and subject characteristics by multiple logistic regression.
aOR (95% CI) P value
Age (vs. 2–8 years)
 Without concomitant knee arthropathy
 9–19 years 1.7 (1.2–2.5) 0.002
 20–44 years 1.4 (1.0–2.0) 0.063
 45–69 years 1.4 (0.9–2.1) 0.206
 With concomitant knee arthropathy
 9–19 years 1.7 (1.0–2.9) 0.069
 20–44 years 1.7 (1.0–2.9) 0.060
 45–69 years 3.4 (1.9–5.9) <0.0001
Haemophilia A (vs. B) 1.3 (1.0–1,4) 0.028
Haemophilia severity (vs. mild)
 Moderate 1.2 (1.0–1.5) 0.062
 Severe 1.3 (1.0–1.5) 0.022
High-titre inhibitor 1.4 (1.1–1.7) 0.010
Elevated BMI (vs. normal)
 Without concomitant knee arthropathy
 Overweight 1.4 (1.1–1.8) 0.014
 Obese 2.1 (1.6–2.8) <0.0001
 With concomitant knee arthropathy
 Overweight 1.1 (0.9–1.3) 0.537
 Obese 1.2 (0.9–1.5) 0.201
Concomitant Ankle arthropathy 1.7 (1.4–1.9) <0.0001
Prophylaxis 0.9 (0.8–1.1) 0.288
aOR(95% CI): adjusted odds ratio and 95% confidence interval.
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